Skip to content
10-Q

Quarterly Report

Cascadian Therapeutics, Inc.

0001387131-17-005347

← back to feed
Filed
Nov 8, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2017 · Nov 8, 2017 50.56M sh
Capex Q3 2017 · Sep 30, 2017 $536K
Capex Q3 2017 · Sep 30, 2016 $74K
Short Term Investments Q3 2017 · Sep 30, 2017 $89.26M
Short Term Investments Q3 2017 · Dec 31, 2016 $49.08M
Cash And Equivalents Q3 2017 · Sep 30, 2017 $12.74M
Cash And Equivalents Q3 2017 · Dec 31, 2016 $13.72M
Cash And Equivalents Q3 2017 · Sep 30, 2016 $16.55M
Cash And Equivalents Q3 2017 · Dec 31, 2015 $27.85M
Stockholders Equity Q3 2017 · Sep 30, 2017 $124.62M
Stockholders Equity Q3 2017 · Dec 31, 2016 $74.36M
Current Liabilities Q3 2017 · Sep 30, 2017 $8.73M
Current Liabilities Q3 2017 · Dec 31, 2016 $8.77M
Current Assets Q3 2017 · Sep 30, 2017 $103.55M
Current Assets Q3 2017 · Dec 31, 2016 $64.45M
Total Assets Q3 2017 · Sep 30, 2017 $133.39M
Total Assets Q3 2017 · Dec 31, 2016 $83.27M
Sga Expense Q3 2017 · Sep 30, 2017 $3.45M
Sga Expense Q3 2017 · Sep 30, 2017 $9.93M
Sga Expense Q3 2017 · Sep 30, 2016 $3.51M
Sga Expense Q3 2017 · Sep 30, 2016 $14.51M
Rd Expense Q3 2017 · Sep 30, 2017 $10.91M
Rd Expense Q3 2017 · Sep 30, 2017 $31.01M
Rd Expense Q3 2017 · Sep 30, 2016 $7.28M
Rd Expense Q3 2017 · Sep 30, 2016 $20M
Net Income Q3 2017 · Sep 30, 2017 −$14.06M
Net Income Q3 2017 · Sep 30, 2017 −$40.17M
Net Income Q3 2017 · Sep 30, 2016 −$10.77M
Net Income Q3 2017 · Sep 30, 2016 −$47.19M
Operating Income Q3 2017 · Sep 30, 2017 −$14.36M
Operating Income Q3 2017 · Sep 30, 2017 −$40.94M
Operating Income Q3 2017 · Sep 30, 2016 −$10.79M
Operating Income Q3 2017 · Sep 30, 2016 −$54.25M